N-methyl-4-nitro-α-naphthylamine | 7000-88-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-methyl-4-nitro-α-naphthylamine
• 英文别名: 1-(methylamino)-4-nitronaphthalene；methyl-(4-nitro-[1]naphthyl)-amine；Methyl-(4-nitro-[1]naphthyl)-amin；4-Nitro-1-methylamino-naphthalin；4-Nitro-N-methyl-<1>naphthylamin；N-Methyl-4-nitro-<1>naphthylamin；N-methyl-4-nitro-1-naphthalenamine；N-methyl-4-nitronaphthalen-1-amine
• CAS: 7000-88-6
• 化学式: C₁₁H₁₀N₂O₂
• 分子量: 202.213
• InChiKey: VQTLBVWZZPYTLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-methyl-4-nitro-α-naphthylamine 、 碘甲烷 以65%的产率得到
  参考文献：
  名称：

  KURASOV, L. A.;POZHARSKIJ, A. F.;KUZMENKO, V. V.;KLYUEV, N. A.;CHERNYSHEV+, ZH. ORGAN. XIMII, 1983, 19, N 3, 590-597

  摘要：

  DOI：
• 作为产物：
  描述：

  1-氯-4-硝基萘 、 甲胺 生成 N-methyl-4-nitro-α-naphthylamine
  参考文献：
  名称：

  Krol et al., Recueil des Travaux Chimiques des Pays-Bas, 1952, vol. 71, p. 545,548

  摘要：

  DOI：

文献信息

• PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS
  申请人：Janssen Biotech, Inc.

  公开号：US20180170909A1

  公开（公告）日：2018-06-21

  Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 5 , G 1 , and G 2 are defined herein.

  揭示了一种通过调节MALT1来治疗受影响的疾病、综合症、症状和疾病的化合物、组合物和方法。这些化合物由以下式（I）表示：其中R1、R2、R3、R4、R5、R6、R5、G1和G2在此处定义。
• A Simple and Effective Procedure for theN-Permethylation of Amino-Substituted Naphthalenes
  作者：Vladimir I. Sorokin、Valery A. Ozeryanskii、Alexander F. Pozharskii

  DOI：10.1002/ejoc.200390085

  日期：2003.2

  ohols) with good to excellent yields. Steric hindrance does not prevent the reaction. Some amines with electron-withdrawing groups, especially at nonconjugated positions, are also alkylated. The procedure allows the combination of a reduction (catalytic or by tin dichloride in acidic media) and a methylation in a one-pot process. (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003)

  多种氨基取代的萘可以通过 Me2SO4/Na2CO3/H2O（醇）系统进行 N-全甲基化，收率非常好。空间位阻不会阻止反应。一些带有吸电子基团的胺，特别是在非共轭位置，也被烷基化。该程序允许在一锅法中将还原（催化或通过酸性介质中的二氯化锡）和甲基化相结合。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003)
• [EN] S-TRIAZOLYL a-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE<br/>[FR] S-TRIAZOLYL $G(A)-MERCAPTOACETANILDES TENANT LIEU D'INHIBITEURS DE LA TRANSCRIPTASE INVERSE VIH
  申请人：VALEANT RES & DEV

  公开号：WO2006026356A2

  公开（公告）日：2006-03-09

  A series of S-triazolyl α-mercaptoacetanilides having general structure (1) are provided, where Q is CO2H, CONR2, SO3H, or SO2NR2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.

  提供一系列具有通用结构（1）的S-三唑基α-巯基乙酰苯胺，其中Q为CO2H、CONR2、SO3H或SO2NR2。这些化合物抑制了HIV的几种逆转录酶变异体，并可用于治疗HIV感染。
• Photosubstitution of 1-methoxy-4-nitronaphthalene with amine nucleophiles: dual pathways
  作者：Nigel J. Bunce、Stephen R. Cater、J. C. Scaiano、Linda J. Johnston

  DOI：10.1021/jo00228a012

  日期：1987.9
• A comparative study between excess-dose users and regular-dose users of rhubarb contained in Kampo medicines
  作者：N. Mantani、T. Kogure、S. Sakai、M. Kainuma、Y. Kasahara、A. Niizawa、Y. Shimada、K. Terasawa

  DOI：10.1078/09447110260571580

  日期：2002.1

  With prolonged use of rhubarb-containing Kampo medicines, some patients come to ask for highdose rhubarb because of deteriorated reactivity to rhubarb. We divided patients into two groups in terms of rhubarb-dose, and compared clinical backgrounds between regular-dose group and excess-dose group. Patients who were treated with rhubarb-containing Kampo extracts (manufactured prescriptions) or Kampo formulae (decoctions) for more than 12 months were enrolled. These two groups were compared for age, sex, shape of stool, abdominal symptoms, existence of hemorrhoids, Kampo diagnosis of abdomen, past stimulant laxative use, duration of stimulant laxative use before the first administration of rhubarb, duration of rhubarb use in our hospital, and initial existence of stimulant pain caused by taking stimulant laxatives for the first time. No significant difference was shown between the two groups in terms of age, duration of stimulant laxative-use before the first prescription of rhubarb, shape of stool, abdominal symptoms, existence of hemorrhoids, or duration of rhubarb-use. However, most patients in the regular-dose group had initial stimulant pain of the abdomen upon taking stimulant laxatives for the first time, but most patients in the excess-dose group did not (p < 0.001). All patients except one in the regular dose group had the sign of "umbilical region tenderness on pressure", but half of the excess-dose group did not have it (P = 0.041). Based on these findings, the absence of "initial stimulant pain" and the absence of "umbilical region tenderness on pressure" may predict increasing or excess use of rhubarb, and long-term use of rhubarb should be discouraged more strongly in the patients without these signs.